학술논문

First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
Document Type
Article
Source
Journal of Nuclear Medicine; Mar2024, Vol. 65 Issue 3, p386-393, 8p
Subject
Language
ISSN
01615505